Use of tumor necrosis factor-alpha inhibitors during pregnancy among women who delivered live born infants.
Efe EworukeGenna PanucciMargie GouldingRosemarie NeunerSengwee TohPublished in: Pharmacoepidemiology and drug safety (2018)
There was a preference for etanercept among pregnancies with AS/JIA/PsA/PsO/RA, despite the availability of other TNFis. Decline in TNFi use after the first trimester may be related to the desire to reduce TNFis transplacental transfer and to minimize infection risk to the fetus or baby associated with live vaccine immunizations after birth.
Keyphrases
- gestational age
- rheumatoid arthritis
- pregnancy outcomes
- juvenile idiopathic arthritis
- preterm birth
- prostate cancer
- ankylosing spondylitis
- disease activity
- polycystic ovary syndrome
- rheumatoid arthritis patients
- pregnant women
- low birth weight
- breast cancer risk
- cervical cancer screening
- preterm infants
- systemic lupus erythematosus
- metabolic syndrome
- insulin resistance
- idiopathic pulmonary fibrosis